Factors in Antipsychotic Drug Selection: Tolerability Considerations

CNS Spectrums

Volumn 8, Issue S2, 2003, Pages 23-25

  Nasrallah, Henry A ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CORTICOSTEROID; LITHIUM; NORGESTREL; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VALPROIC ACID;

AKATHISIA; AMENORRHEA; ANOVULATION; AZOOSPERMIA; BIPOLAR DISORDER; COMORBIDITY; CONFERENCE PAPER; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPHORIA; DYSTONIA; ERECTILE DYSFUNCTION; FAMILY HISTORY; FATIGUE; GALACTORRHEA; GENETIC LINKAGE; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; LIPID BLOOD LEVEL; MANIA; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; METABOLIC REGULATION; MOTOR DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; POLYDIPSIA; POLYURIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RETINOPATHY; RISK FACTOR; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; VISUAL IMPAIRMENT; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1642501785     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900008166     Document Type: Article

References (20)

1. Tandon, R, Jibson, MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003; 28(suppl 1):9–26.
2. Casey, DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl. 1994; 380: 14–20.
3. Lemmens, P, Brecher, M, Van Baelen, B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999; 99: 160–170.
4. Tandon, R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr Q. 2002; 73: 297–311.
5. Marken, PA, Haykal, RF, Fisher, JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992; 11: 851–856.
6. Petty, RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999; 35(suppl):S67–S73.
7. David, SR, Taylor, CC, Kinon, BJ, Breier, A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000; 22: 1085–1096.
8. Allison, DB, Mentore, JL, Heo, M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156: 1686–1696.
9. Kane, JM, Carson, WH, Saha, AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63: 763–771.
10. Beasley, CM Jr. Safety of olanzapine. Monograph 15. J Clin Psychiatry. 1997; 14: 19–21.
11. Weiden, P, Mackell, J, MacDonell, D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. In press.
12. Koller, E, Schneider, B, Bennett, K, Dubitsky, G. Clozapine-associated diabetes. Am J Med. 2001; 111: 716–723.
13. Muench, J, Carey, M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract. 2001; 14: 278–282.
14. Koller, EA, Doraiswamy, PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002; 22: 841–852.
15. Koller, E. US Food and Drug Administration. FDA MedWatch. 2001, 2002.
16. Ganzini, L, Heintz, RT, Hoffman, WF, Casey, DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry. 1991; 48: 259–263.
17. Raja, M, Azzoni, A. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. Hum Psychopharmacol. 2002; 17: 61–63.
18. Glick, ID, Romano, SJ, Simpson, G, et al. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled 6-week trial. Poster presented at: 154th Annual Meeting of the American Psychiatric Association; May 7–11, 2001; New Orleans, La.
19. McQuade, RD, Jody, D, Kujawa, MJ, et al. Long-term weight effects of aripiprazole versus olanzapine. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17–22, 2003; San Francisco, Calif.
20. Koro, CE, Fedder, DO, L'Italien, GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59: 1021–1026.